US equities |
SPCX $174.71 ▲+2.12% NVDA $242.07 ▲+1.33% MU $1,062.22 ▼-0.16% MRVL $290.37 ▲+7.05% AMD $646.90 ▲+2.40% SNDK $1,673.59 ▼-1.79% TSLA $381.66 ▲+0.77% AVGO $376.52 ▲+3.87%
FinancialContent

Neurogene Inc. - Common Stock (NQ:NGNE)

25.17 -1.30 (-4.91%)
Delayed Quote Updated: 10:20 AM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neurogene Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Inc. Announces Pricing of $125 Million Public Offering
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Inc. Announces Proposed Public Offering
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene to Participate in Stifel 2026 Virtual CNS Forum
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
Which stocks are moving on Friday? ↗
Via Chartmill
News headline image
Why Did NGNE Stock Surge 25% In Pre-Market Today? ↗
The company said that the U.S. Food and Drug Administration granted a key designation for its investigational gene therapy targeting Rett syndrome. 
Via Stocktwits
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene to Participate in Upcoming Investor Conferences
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
< Previous 1 2 3 4 Next >